Table 2.
Post-booster geometric mean concentrations (GMCs) of tetanus antibody and pre- to post-booster level ratio including the 95% confidence interval
| Predictors | Post-GMCs (95% CI) in UI/ml | P | Pre- to post-booster level ratio (95% Cl) | P |
|---|---|---|---|---|
| Sex | ||||
| Male | 7.7 (7.1–8.4) | 0.162 | 6.9 (5.7–8.3) | 0.114 |
| Female | 7.9 (7.1–8.9) | 8.3 (6.7–10.1) | ||
| Vaccine | ||||
| Tetavax | 8.3 (7.6–9.1) | 0.186 | 7.3 (6.1–8.9) | 0.860 |
| Vacteta | 7.4 (6.6–8.2) | 7.8 (6.3–9.5) | ||
| Smoker | ||||
| Yes | 7.3 (6.2–8.6) | 0.213 | 6.7 (4.8–9.4) | 0.182 |
| No | 8.0 (7.4–8.7) | 7.8 (6.7–9.1) | ||
| Concomitant medication | ||||
| Yes | 7.4 (6.4–8.5) | 0.588 | 7.1 (5.9–8.7) | 0.588 |
| No | 8.1 (7.5–8.8) | 7.8 (6.4–9.4) | ||
| Related adverse events | ||||
| Yes | 8.6 (7.4–9.9) | 0.071 | 7.6 (5.9–9.6) | 0.993 |
| No | 7.6 (7.0–8.3) | 7.4 (6.2–8.9) | ||
| Age (median) | ||||
| ⩽43.8 years | 7.7 (6.9–8.5) | 0.641 | 8.6 (7.0–10.6) | 0.103 |
| >43.8 years | 8.0 (7.3–8.8) | 6.6 (5.5–7.9) | ||
| BMI (median) | ||||
| ⩽25.8 kg/m2 | 7.8 (7.0–8.7) | 0.856 | 7.5 (6.1–9.3) | 0.997 |
| >25.8 kg/m2 | 7.9 (7.2–8.6) | 7.6 (6.3–9.1) | ||
| Pre-vaccination period (median) | ||||
| ⩽12.6 years | 8.1 (7.4–8.9) | 0.615 | 7.1 (5.9–8.5) | 0.331 |
| >12.6 years | 7.6 (6.8–8.5) | 8.0 (6.5–9.8) | ||
| Pre-vaccination GMC (median) | ||||
| ⩽1.2 IU/ml | 7.1 (6.3–8.0) | 0.033 | 15.8 (13.9–18.1) | <0.0001 |
| >1.2 IU/ml | 8.7 (8.0–9.3) | 3.4 (3.1–3.9) | ||
| Post-vaccination period (median) | ||||
| ⩽28 days | 7.4 (6.7–8.3) | 0.221 | 7.3 (6.0–8.7) | 0.715 |
| >28 days | 8.3 (7.6–9.2) | 7.9 (6.4–9.7) | ||
P, statistical significance calculated with the Mann–Whitney U test.